The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer.

被引：0
|
作者：
Zhao, Jie [1 ]
Dong, Yiting [1 ]
Bai, Hua [1 ]
Duan, Jianchun [1 ]
Wang, Guoqiang [2 ]
Xu, Jiachen [1 ]
Wang, Zhijie [1 ]
Wang, Jie [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China
[2] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1614
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
  • [32] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    Experimental Hematology & Oncology, 8
  • [33] Clinical and genomic features of high tumor mutation burden in patients with non-small cell lung cancer.
    Qiu, Yuan
    Yang, Haihong
    Chen, Hanzhang
    Deng, Qiuhua
    Liu, Liping
    Xiao, Dakai
    Shao, Di
    Li, Weiwei
    Jiang, Wenxi
    Zhu, Changbin
    Lin, Yongping
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] THE SUM OF TUMOR SIZE PREDICTS THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER
    Shiraishi, Yusuke
    Marumo, Satoshi
    Amimoto, Hisanori
    Yamaki, Haruka
    Shirata, Masahiro
    Imoto, Takamitsu
    Kitajima, Takamasa
    Inoue, Daiki
    Katayama, Yuko
    Fukui, Motonari
    RESPIROLOGY, 2018, 23 : 289 - 289
  • [35] Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Leger, Paul Denis
    Rothschild, Sasha
    Castellanos, Emily
    Pillai, Rathi Narayana
    York, Sally Jane
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] The positive correlation between tumor mutation burden and the purity of tumor samples in non-small cell lung cancer and colorectal cancer.
    Tong, Jian
    Zhang, Xiaoni
    Qu, Hongyue
    Yang, Qing
    Duan, Jingxian
    Xu, Mingyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Retrospective analysis of efficacy of immune checkpoint inhibitors in BRCA-mutant non-small cell lung cancer.
    Chen, Shaomu
    Li, Si
    Chen, Dongsheng
    Xiao, Mingzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Efficacy of checkpoint inhibitors, tumor vaccines, and cellular immunotherapies in patients with advanced non-small cell lung cancer.
    Yu, Yunfang
    Ou, Qiyun
    Wang, Ying
    Liu, Zhifeng
    Fu, Tuping
    Gao, Quanlong
    Lin, Dagui
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [39] Robust prediction of immune checkpoint inhibition therapy for non-small cell lung cancer.
    Zhang, Yiqun
    Zhao, Guodong
    He, Ning
    Wang, Lingyu
    Wang, Jianfei
    Jin, Ge
    Lin, Rongbo
    Yang, Yadong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
    Matsuo, Norikazu
    Azuma, Koichi
    Murotani, Kenta
    Murata, Daiki
    Matama, Goushi
    Kawahara, Akihiko
    Kojima, Takashi
    Tokito, Takaaki
    Hoshino, Tomoaki
    THORACIC CANCER, 2023, 14 (15) : 1362 - 1367
12345